Login
CASTLE BIOSCIENCES INC logo

CASTLE BIOSCIENCES INC

castlebiosciences.com

What Do They Do?

Provides molecular diagnostic tests that help clinicians diagnose and guide treatment for dermatologic cancers, Barrett’s esophagus, atopic dermatitis and uveal melanoma.

How Do They Make Money?

Clinicians order tests, and the company bills third-party payors and patients when it delivers the test report. Payments are mainly from Medicare and commercial insurers, and timing varies with payor practices and coverage agreements.

revenue
SegmentShareRevenue
Dermatologic
Sold outright

63%
FY2022: 91%
Non Dermatologic
Sold outright

37%
FY2022: 8.9%

Who Are Their Customers?

Treating clinicians order the tests; the company bills third-party payors, including Medicare and commercial insurers, and patients. Its sales team markets directly to clinicians and associated personnel.

Customers above 10% of revenue, FY2025
of revenue from two customers (44%, 16%)
FY2024: 47% from one customer

Do Revenues Turn Into Profits?

Not on paper. It lost $24.2M in FY2025, but brought in more cash than it spent: $28.3M of free cash flow.

Operating income, FY2025
−12% of revenue
▼ Turned to a loss vs FY2024 ($8.7M, 3%)
Net income, FY2025
−7% of revenue
▼ Turned to a loss vs FY2024 ($18.2M, 5%)
Free cash flow, FY2025
8% of revenue
▼ −22% vs FY2024 ($36.5M, 11%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +24%
vs $83M in Q3 FY2025
Net income
▼ −718% (Loss)
vs −$501K in Q3 FY2025
Dermatologic share of revenue vs 58.4% in Q3 FY2025
  • Jul 30, 2026 Raised full-year revenue guidance 2026 revenue guidance rose to $365-375 million from $345-355 million.
  • May 6, 2026 Raised full-year revenue guidance The 2026 range rose to $345-355 million from $340-350 million.

Growing. Revenue grew 3.7x in 4 years, from $94.1M in FY2021 to $345.7M in FY2025, about 38% a year.

Inflammatory-skin test launch The earlier report described a pipeline test spanning psoriasis, atopic dermatitis and related conditions; the latest report describes AdvanceAD-Tx as a limited-launch test to guide systemic treatment for moderate-to-severe atopic dermatitis.

IDgenetix discontinued The earlier report listed IDgenetix as a test for mental health conditions; the latest report says Castle discontinued it.

DiffDx-Melanoma discontinued The earlier report said MyPath and DiffDx-Melanoma were offered together; the latest report says Castle suspended the clinical offering of DiffDx-Melanoma.

Revenue over time
Dermatologic Non Dermatologic Other
$500M$250M$0

Who Do They Compete With?

Competes with SkylineDx, Interpace Diagnostics, Lucid Diagnostics, and LabCorp

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support